Physician profile
Malcolm G Floyd
NPI 1023323516
$1,997.12
in general payments reported to CMS, 2019-2025
22 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $31.00 · 2021: $29.52 · 2022: $69.71 · 2023: $563 · 2024: $568 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $330.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $265.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $198.78 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $151.47 | 2019-2025 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $141.75 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $114.81 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.53 | 2019-2025 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $81.71 | 2019 | |
| Dexcom, INC. | $79.21 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $74.98 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.23 | 2023 | |
| Merck Sharp & Dohme LLC | $68.19 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Organogenesis INC. | $62.10 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.29 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $35.60 | 2023-2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.00 | 2019-2025 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $31.51 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $25.80 | 2023 | Trintellix |
| Corcept Therapeutics | $24.03 | 2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $19.71 | 2024 | Nuzyra |
| Pfizer INC. | $14.58 | 2020 | |
| Amarin Pharma, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.